AMTI News and Press, Applied Molecular Transport Inc. From 01/19/21

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has appointed Douglas Rich as Chief Technical Officer. In his new role, Douglas will assume leadership re...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadStocks only have one trading day left to end up with one of the strongest Novembers on record as positive news on vaccine...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the...

Applied Molecular Transport (AMTI): Q3 GAAP EPS of -$0.48.Cash, cash equivalents, and investments of $147.3MPress Release For further details see: Applied Molecular Transport reports Q3 results

- Company on track with comprehensive AMT-101 Phase 2 clinical program across multiple indications, including inflammatory bowel diseases and rheumatoid arthritis - - Announced dosing of first patient in Phase 2 monotherapy trial (LOMBARD) evaluating the efficacy and safety of oral AM...

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT, and Bittoo Kanwar, M.D., chief medical offic...

- AMT-101 (oral fusion protein of hIL-10 and AMT carrier) rapidly and efficiently transports through intestinal epithelia in healthy and inflamed conditions to target local intestinal tissue - - Demonstrates minimal systemic exposure of hIL-10 while driving induction of an anti-inflamma...

SOUTH SAN FRANCISCO, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT, and Bittoo Kanwar, M.D., chief medical offi...

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in a randomized, placebo-controlled, double-blind, multicenter Phase 2a study ev...